Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.35 |
| ▸ | MICA | Q29983 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26760225 | 1.00 | EPHX2 (0.43) | EPHX2EPHX1PDK2DPP8DPP7 | |
| SCHEMBL18667410 | 1.00 | EPHX2 (0.43) | EPHX2EPHX1PDK2DPP8DPP7 | |
| SCHEMBL2069876 | 0.89 | EPHX2 (0.52) | EPHX2CYP3A4CYP2C19CHRM2CHRM1 | |
| SCHEMBL4577748 | 0.89 | EPHX1 (0.48) | EPHX2EPHX1PDK2DPP8DPP7 | |
| SCHEMBL18307629 | 0.81 | NR1H2 (0.39) | EPHX2PDK2DPP8DPP7ALOX5 | |
| SCHEMBL3963077 | 0.81 | NR1H2 (0.39) | EPHX2PDK2DPP8DPP7ALOX5 | |
| SCHEMBL1652121 | 0.79 | EPHX1 (0.47) | EPHX2EPHX1KDM1A | |
| SCHEMBL28132227 | 0.78 | LIPE (0.41) | EPHX2PDK2ALOX5CYP3A4CYP2C19 | |
| SCHEMBL27989426 | 0.78 | LIPE (0.41) | EPHX2PDK2ALOX5CYP3A4CYP2C19 | |
| SCHEMBL28132225 | 0.78 | LIPE (0.41) | EPHX2PDK2ALOX5CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | EPHX2 2699/4885EPHX1 2138/4885PDK2 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.